期刊
CHILDREN-BASEL
卷 7, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/children7020014
关键词
acute myeloid leukemia; immunotherapy; chimeric antigen receptor; CAR; bispecific antibodies; BiTE; DART
类别
资金
- Leukemia and Lymphoma Society
- Alex Lemonade Stand Foundation
- St. Baldrick's Foundation
- Cancer Prevention Research Institute of Texas [RP160693]
- Assisi Foundation of Memphis
- American Lebanese Syrian Associated Charities (ALSAC)
Outcomes for pediatric patients with acute myeloid leukemia (AML) remain poor, highlighting the need for improved targeted therapies. Building on the success of CD19-directed immune therapy for acute lymphocytic leukemia (ALL), efforts are ongoing to develop similar strategies for AML. Identifying target antigens for AML is challenging because of the high expression overlap in hematopoietic cells and normal tissues. Despite this, CD123 and CD33 antigen targeted therapies, among others, have emerged as promising candidates. In this review we focus on AML-specific T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cells. We review antigens being explored for T cell-based immunotherapy in AML, describe the landscape of clinical trials upcoming for bispecific antibodies and CAR T cells, and highlight strategies to overcome additional challenges facing translation of T cell-based immunotherapy for AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据